Sagimet Biosciences (STU:0O2) Capital Expenditure: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
18 GF Score
Price €6.10
GF Value €5.69
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Sagimet Biosciences Capital Expenditure?

Sagimet Biosciences STU:0O2 -0.97% 18 Capital Expenditure is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 18/100 and a GF Value™ of €5.69 (Fairly Valued). The stock has 3 warning signs investors should review.

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Sagimet Biosciences's cash flow for capital expenditures for the three months ended in Mar. 2026 was €0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Sagimet Biosciences Capital Expenditure Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Capital Expenditure Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Capital Expenditure
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:0O2
18GF Score
Sagimet Biosciences Inc STU:0O2
Capital Expenditure is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Capital Expenditure →
What does a Capital Expenditure of €0.00 Mil mean?
Sagimet Biosciences (STU:0O2) has a Capital Expenditure of €0.00 Mil as of Mar. 2026. Capital Expenditures represent the company's purchases of property, plant, equipment and other long-term fixed assets. View historical data for Sagimet Biosciences.
Is Sagimet Biosciences' Capital Expenditure too high?
Sagimet Biosciences' current Capital Expenditure is €0.00 Mil. Overall, Sagimet Biosciences has a GF Score™ of 18/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Capital Expenditure compare to EDIT and AUTL?
Sagimet Biosciences' Capital Expenditure of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capital Expenditure for a Biotechnology company?
A good Capital Expenditure depends on the Biotechnology industry context. However, Capital Expenditure should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capital Expenditure mean?
A high Capital Expenditure can signal that a stock is expensive relative to its fundamentals. Capital Expenditures represent the company's purchases of property, plant, equipment and other long-term fixed assets. View historical data for Sagimet Biosciences. Sagimet Biosciences's current Capital Expenditure is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Fairly Valued. The stock's GF Value™ is €5.69, compared to a current price of €6.10 — trading 7.2% above its estimated fair value. The current Capital Expenditure is €0.00 Mil. Sagimet Biosciences' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capital Expenditure calculated?
Capital Expenditure is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Capital Expenditure is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?

Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued. The current stock price of €6.10 is trading 7.2% above its estimated GF Value™ of €5.69. GuruFocus considers Sagimet Biosciences to be Fairly Valued.

Key valuation signals for STU:0O2:

  • Capital Expenditure: €0.00 Mil
  • GF Value™: €5.69 vs. price of €6.10 (7.2% above fair value)
  • GF Score™: 18/100 with 3 warning signs

No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score

Get the complete analysis for STU:0O2

Capital Expenditure is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.10
Price
€5.69
GF Value